Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02042053 · ClinicalTrials.gov registry record · NA
PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer
A NA study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02042053 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 10 participants.
The verdict
NCT02042053, a NA study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study intents to provide an initial evaluation of the utility of positron emission tomography and magnetic resonance (PET/MR) imaging measures for the prediction of immunological response to Sipuleucel T (SipT) therapy.
Interventions
- DEVICE PET/MRI
- DEVICE PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02042053
The ClinicalTrials.gov registry entry for NCT02042053 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PET/MRI is the first listed.
NCT02042053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02042053 about?
NCT02042053 is a clinical study titled "PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer". This study intents to provide an initial evaluation of the utility of positron emission tomography and magnetic resonance (PET/MR) imaging measures for the prediction of immunological response to Sipuleucel T (SipT) therapy.
What is the current status of trial NCT02042053?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2014-01. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02042053?
The interventions under investigation include: PET/MRI (DEVICE), PET/CT (DEVICE).
Who is sponsoring clinical trial NCT02042053?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.